CHA2DS2-VASc Calculator
Estimate stroke risk in atrial fibrillation using the CHA2DS2-VASc score.
What Is the CHA₂DS₂-VASc Score?
The CHA₂DS₂-VASc score is a clinical risk stratification tool used to estimate the annual stroke risk in patients with atrial fibrillation (AFib). It assigns points based on specific risk factors to help clinicians determine whether anticoagulation therapy is warranted. The acronym stands for Congestive heart failure, Hypertension, Age ≥75 years (2 points), Diabetes, Stroke/TIA/thromboembolism (2 points), Vascular disease, Age 65–74 years, and Sex category (female).
How the Score Is Calculated
The calculator assigns points based on patient characteristics. Each risk factor contributes to a total score ranging from 0 to 9. The scoring breakdown is as follows:
| Risk Factor | Points |
|---|---|
| Congestive heart failure (signs/symptoms of left ventricular dysfunction) | 1 |
| Hypertension (resting blood pressure >140/90 mmHg or on treatment) | 1 |
| Age ≥75 years | 2 |
| Diabetes mellitus (fasting glucose >125 mg/dL or on treatment) | 1 |
| Stroke, TIA, or systemic embolism (prior event) | 2 |
| Vascular disease (prior MI, peripheral artery disease, or aortic plaque) | 1 |
| Age 65–74 years | 1 |
| Sex category (female) | 1 |
The total score correlates with an estimated annual stroke risk. A score of 0 in males or 1 in females generally indicates low risk, while higher scores suggest increasing benefit from oral anticoagulation.
Interpreting Your Results
The calculated score provides a numerical estimate of stroke risk, but it is not a diagnosis. The score is used alongside clinical judgment to guide treatment decisions. General interpretation guidelines are:
- Score 0 (male) or 1 (female): Low annual stroke risk (under 1%). Anticoagulation is typically not recommended.
- Score 1 (male): Moderate risk. Consider anticoagulation based on individual patient factors and bleeding risk.
- Score ≥2: High annual stroke risk. Oral anticoagulation is generally recommended unless contraindicated.
These thresholds align with major clinical guidelines, including those from the ESC and ACC/AHA. The score does not account for bleeding risk, which should be assessed separately using tools like HAS-BLED.
Common Misconceptions
Several points about the CHA₂DS₂-VASc score are frequently misunderstood:
- It does not replace clinical judgment. The score is a guide, not a rule. Patient preferences, bleeding risk, and comorbidities must be considered.
- Age is weighted heavily. Age ≥75 years contributes 2 points, reflecting its strong association with stroke risk. A patient aged 75 with no other risk factors still scores 2.
- Sex category is not a standalone risk factor. Female sex only adds a point if other risk factors are present. A female with a score of 0 has the same low risk as a male with a score of 0.
- The score is validated for non-valvular AFib. It is less reliable for patients with valvular atrial fibrillation or mechanical heart valves.
Limitations of the CHA₂DS₂-VASc Score
While widely used, the score has limitations that should be acknowledged:
- Does not include all risk factors. Factors such as renal impairment, obesity, or left atrial size are not captured.
- Assumes a linear relationship between risk factors and stroke risk, which may not hold in all populations.
- Population-specific variations exist. The score was derived from a European cohort and may perform differently in other ethnic groups.
- Does not predict bleeding risk. A high CHA₂DS₂-VASc score often correlates with higher bleeding risk, but the two must be assessed independently.
Practical Use Cases
The CHA₂DS₂-VASc calculator is used in several clinical scenarios:
- Initial AFib diagnosis: To determine whether anticoagulation is appropriate.
- Pre-procedural assessment: Before cardioversion or catheter ablation to evaluate stroke risk.
- Treatment monitoring: To reassess risk if a patient's clinical status changes (e.g., new hypertension or diabetes diagnosis).
- Patient education: To visually communicate stroke risk and the rationale for anticoagulation.
Frequently Asked Questions
What is the difference between CHADS₂ and CHA₂DS₂-VASc?
CHA₂DS₂-VASc is an expanded version of the older CHADS₂ score. It adds additional risk factors (vascular disease, age 65–74, and female sex) and provides better discrimination, especially for patients with low to moderate risk. CHA₂DS₂-VASc is now recommended by most major guidelines over CHADS₂.
Can the CHA₂DS₂-VASc score be used for patients with valvular AFib?
The score was developed and validated for non-valvular atrial fibrillation. For patients with valvular AFib (e.g., rheumatic mitral stenosis) or mechanical heart valves, different risk assessment and anticoagulation strategies apply. Consult current guidelines for these populations.
What does a CHA₂DS₂-VASc score of 0 mean?
A score of 0 in a male or 1 in a female indicates a low annual stroke risk (typically under 1%). Anticoagulation is generally not recommended in these cases, as the bleeding risk from therapy may outweigh the benefit.
How often should the CHA₂DS₂-VASc score be recalculated?
The score should be reassessed whenever a patient's clinical status changes. For example, if a patient develops hypertension, diabetes, or reaches age 65 or 75, the score should be updated. Annual reassessment is a reasonable practice for stable patients.
Does the CHA₂DS₂-VASc score account for bleeding risk?
No. The score only estimates stroke risk. Bleeding risk should be assessed separately using tools like HAS-BLED or ORBIT. A high CHA₂DS₂-VASc score often correlates with higher bleeding risk, but both must be evaluated independently before starting anticoagulation.